Skip to main content
Kolon TissueGene, Inc. logo

Kolon TissueGene, Inc. — Investor Relations & Filings

Ticker · 950160 ISIN · KR8840120008 LEI · 5493000SYYLC88FUL781 KO Manufacturing
Filings indexed 288 across all filing types
Latest filing 2018-11-20 Regulatory Filings
Country US United States of America
Listing KO 950160

About Kolon TissueGene, Inc.

https://www.tissuegene.com/

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic diseases and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, allogeneic cell and gene therapy designed to treat knee osteoarthritis. The therapy aims to reduce pain, improve joint function, and slow the progression of the disease. TG-C is currently in late-stage clinical development, undergoing Phase 3 trials.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow) for Kolon TissueGene. It provides details such as the date, location, target audience, and purpose of the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it fits the regulatory filing format for corporate events, it is classified as a Regulatory Filing (RNS).
2018-11-20 Korean
투자판단관련주요경영사항(기술수출 계약체결)
M&A Activity Classification · 95% confidence The document is a regulatory filing from Kolon TissueGene regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically announcing a technology export contract (licensing agreement) with Mundipharma. Since this is a specific corporate announcement regarding a material business event (licensing deal) and does not fit into categories like M&A (which usually refers to corporate mergers/acquisitions) or other specific financial reports, it is best classified as a general regulatory filing (RNS).
2018-11-19 Korean
분기보고서 (2018.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Kolon TissueGene, Inc. covering the period from January 1, 2018, to September 30, 2018. It contains detailed financial statements, management discussions, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2018
2018-11-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.